<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To test the contribution of programmed cell <z:hpo ids='HP_0011420'>death</z:hpo> 4 (PDCD4) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor gene in Barrett's <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: PDCD4 immunohistochemical expression was assessed in 88 biopsy samples obtained from histologically proven long-segment Barrett's mucosa (BM; 25 non-intestinal columnar <z:mpath ids='MPATH_160'>metaplasia</z:mpath>, 25 <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> (IM), 16 low-grade intraepithelial <z:hpo ids='HP_0002664'>neoplasia</z:hpo> (LG-IEN), 12 high-grade IEN (HG-IEN) and 10 Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (BAc)) </plain></SENT>
<SENT sid="2" pm="."><plain>As controls, 25 additional samples of native oesophageal mucosa (N) were obtained from patients with <z:e sem="disease" ids="C0013395" disease_type="Disease or Syndrome" abbrv="">dyspepsia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>To further support the data, the expression levels of miR-21, an important PDCD4 expression regulator, in 14 N, 5 HG-IEN and 11 BAc samples were determined by quantitative real-time PCR analysis </plain></SENT>
<SENT sid="4" pm="."><plain>Results PDCD4 immunostaining decreased progressively and significantly with the progression of the phenotypic changes occurring during Barrett's <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> (p&lt;0.001) </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_458'>Normal</z:mpath> basal squamous epithelial layers featured strong PDCD4 nuclear immunoreaction (mostly coexisting with weak-moderate cytoplasmic staining) </plain></SENT>
<SENT sid="6" pm="."><plain>Non-intestinal columnar <z:mpath ids='MPATH_160'>metaplasia</z:mpath> and <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> preserved a strong nuclear immunostaining; conversely, a significant decrease in PDCD4 nuclear expression was seen in dysplastic (LG-IEN and HG-IEN) and neoplastic lesions </plain></SENT>
<SENT sid="7" pm="."><plain>Weak-moderate cytoplasmic immunostaining was evident in cases of LG-IEN, while HG-IEN and BAc samples showed weak cytoplasmic or no protein expression </plain></SENT>
<SENT sid="8" pm="."><plain>As expected, miR-21 expression was significantly upregulated in HG-IEN and BAc samples, consistently with PDCD4 dysregulation </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These data support a significant role for PDCD4 downregulation in the progression of BM to BAc, and confirm miR-21 as a negative regulator of PDCD4 in vivo </plain></SENT>
<SENT sid="10" pm="."><plain>Further efforts are needed to validate PDCD4 as a potential prognostic marker in patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
</text></document>